SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MEDX ... anybody following?
MEDX 31.58+1.4%Nov 5 12:44 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Icebrg9/28/2007 5:30:45 PM
  Read Replies (1) of 2240
 
Meanwhile, Medarex shares fell as Zhang [BMO Capital Markets] issued an "Underperform" rating and $11 price target, expecting the company's lead drug candidate ipilimumab to yield poor results in its ongoing melanoma study. Data from the study will likely be insufficient for approval, he said, and called the rest of the company's product pipeline "lackluster."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News